Evoke Pharma Inc (EVOK) - Total Liabilities
Based on the latest financial reports, Evoke Pharma Inc (EVOK) has total liabilities worth $12.29 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Evoke Pharma Inc to track the company's year-over-year net asset growth rate.
Evoke Pharma Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Evoke Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Evoke Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
China | CN¥310.62 Million |
|
FAR Ltd
AU:FAR
|
Australia | AU$6.08 Million |
|
SUNEX S.A.
WAR:SNX
|
Poland | zł205.21 Million |
|
The Navakij Insurance Public Company Limited
BK:NKI
|
Thailand | ฿3.54 Billion |
|
RENN Fund Inc
NYSE MKT:RCG
|
USA | $95.59K |
|
Enero Group Ltd
AU:EGG
|
Australia | AU$65.79 Million |
|
BIT Mining Limited
NYSE:BTCM
|
USA | $14.82 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Evoke Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVOK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evoke Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evoke Pharma Inc (2011–2024)
The table below shows the annual total liabilities of Evoke Pharma Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.48 Million | +8.63% |
| 2023-12-31 | $9.65 Million | +24.22% |
| 2022-12-31 | $7.77 Million | +10.67% |
| 2021-12-31 | $7.02 Million | -44.52% |
| 2020-12-31 | $12.65 Million | +527.70% |
| 2019-12-31 | $2.02 Million | +23.29% |
| 2018-12-31 | $1.63 Million | -71.70% |
| 2017-12-31 | $5.78 Million | +4.89% |
| 2016-12-31 | $5.51 Million | -9.24% |
| 2015-12-31 | $6.07 Million | -0.75% |
| 2014-12-31 | $6.11 Million | +60.73% |
| 2013-12-31 | $3.80 Million | -80.77% |
| 2012-12-31 | $19.78 Million | +6.55% |
| 2011-12-31 | $18.56 Million | -- |
About Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more